Septerna (NASDAQ:SEPN) Downgraded to “Sell” Rating by Wall Street Zen

Septerna (NASDAQ:SEPN) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

SEPN has been the subject of a number of other research reports. Cantor Fitzgerald reissued an “overweight” rating and set a $25.00 target price on shares of Septerna in a research report on Friday, September 5th. Wells Fargo & Company increased their target price on shares of Septerna from $11.00 to $18.00 and gave the company an “equal weight” rating in a research report on Friday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $26.00 target price on shares of Septerna in a research report on Thursday, August 21st. Four equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and an average price target of $26.75.

Septerna Price Performance

Septerna stock opened at $14.28 on Friday. The business has a 50 day moving average of $12.47 and a 200-day moving average of $9.41. Septerna has a 1 year low of $4.17 and a 1 year high of $28.99. The company has a market capitalization of $636.60 million and a P/E ratio of -1.42.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.51). Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. The firm had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Equities analysts anticipate that Septerna will post -7.11 EPS for the current year.

Hedge Funds Weigh In On Septerna

Institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE bought a new position in shares of Septerna during the 4th quarter worth approximately $1,803,000. Jane Street Group LLC bought a new position in shares of Septerna during the 4th quarter worth approximately $600,000. The Manufacturers Life Insurance Company bought a new position in shares of Septerna during the 4th quarter worth approximately $506,000. Nuveen LLC bought a new position in shares of Septerna during the 1st quarter worth approximately $139,000. Finally, Northern Trust Corp bought a new position in shares of Septerna in the 4th quarter worth $3,384,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.